JASPER THERAPEUTICS INC
JSPR · NASDAQ
Updated at 2026-10-13 15:18:11
- Today's High
- $0.55
- Today’s Low
- $0.51
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $0.56
- Previous Close
- $0.55
- Volume
- 335.8K
- Market Cap
- $18.46M
- P/E Ratio
- --
- EPS
- $-1.57
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Biotechnology
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- 2200 BRIDGE PKWY, REDWOOD CITY, CA, UNITED STATES, 94065
- Country
- US
- Listing Date
- 2019-11-20
- Fiscal Year End
- December
- Shares Outstanding
- 33.27M
- CIK
- 0001788028
- Website
- jaspertx.com
Jasper Therapeutics Inc (JSPR) is a pioneering biopharmaceutical company dedicated to advancing hematopoietic stem cell therapies aimed at improving treatment outcomes for patients suffering from severe conditions such as sickle cell disease and specific hematologic malignancies. Leveraging state-of-the-art technologies, Jasper seeks to minimize transplant-related complications, addressing critical unmet needs in the hematology and oncology fields. Supported by a robust intellectual property portfolio and strategic collaborations, the company is well-positioned to drive innovation and propel its clinical pipeline forward, underscoring its commitment to transformative solutions in regenerative medicine.
Financial Metrics
Revenue
2026-06-30
$0
2026-03-31
$0
2025-12-31
$0
2025-09-30
$0
Operating Expenses
2026-06-30
$9.2M
2026-03-31
$10.93M
2025-12-31
$15.83M
2025-09-30
$19.16M
Net Income
2026-06-30
-$2.76M
2026-03-31
-$1.17M
2025-12-31
-$9.1M
2025-09-30
-$18.73M
Net Profit Margin
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
Earnings Per Share
2026-06-30
$-0.24
2026-03-31
$-0.38
2025-12-31
$-0.54
2025-09-30
$-1.13
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$2.73M
2026-03-31
-$1.15M
2025-12-31
-$8.81M
2025-09-30
-$18.5M
Effective Tax Rate
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating Expenses | $9.2M | $10.93M | $15.83M | $19.16M |
| Net Income | -$2.76M | -$1.17M | -$9.1M | -$18.73M |
| Net Profit Margin | -- | -- | -- | -- |
| Earnings Per Share | $-0.24 | $-0.38 | $-0.54 | $-1.13 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$2.73M | -$1.15M | -$8.81M | -$18.5M |
| Effective Tax Rate | -- | -- | -- | -- |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.